Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist

MANCHESTER, NH--(Marketwired - Jul 9, 2014) - Boston Therapeutics, Inc. ( OTCQB : BTHE ), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the Company's science and technology. He will serve as the primary liaison to the Company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the Board of Directors' Scientific Advisory Committee.

Dr. Rivnay is a seasoned director of technology and research activities within the biotechnology industry. Most recently, he was Director of Research and Development at Formatech Inc., where he managed more than 50 projects on formulation development for a diverse group of drugs, as well as studies for stability and material compatibility, initial engineering and process development activities, and preparation of non-cGMP product lots for toxicology studies and other research purposes. Prior to this, he was Vice President of Research and Development and Lab Director at Repromedix Corporation, where he introduced more than 50 new test products for both male and female infertility. Earlier, he served as Senior Investigator and Program Leader at Procept Inc., where he initiated and led a new R&D program focusing on the development of anti-allergic drugs, and as Senior Scientist at Neurex Corporation. He holds a Ph.D. in biochemistry from The Weizmann Institute of Science and a B.Sc. in biology from Tel Aviv University.

Dr. Rivnay said, "Through my decades of work in the biotech industry, I have come to appreciate the importance of innovation and the need for new approaches in various therapeutic areas. It is my belief that there is a continuing need to close the gap between academic discoveries and the market, by intensive corporate translational R&D activity. The work Boston Therapeutics has done in the area of diabetes is well positioned with this philosophy. The molecular mechanism of action of BTI-320 is related to a-amylase, a key enzyme responsible for the breakdown of starch in the human body. I look forward to overseeing these efforts and working with the other members of the management team and the medical advisory board as we continue to develop our products and work to secure patents."

David Platt, Chief Executive Officer of Boston Therapeutics, said, "We are truly fortunate that Benjamin Rivnay, with his impressive breadth of experience, has chosen to join the Company as Chief Scientist. His professional background ideally places him to oversee our anticipated growth in research, science and technological innovations through the coming years. We anticipate that his insights will drive us to further success as an innovator in the diabetes market."

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, ( OTCQB : BTHE ) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a new generation of Alpha Glucosidase Inhibitor, is a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation. The Company is currently enrolling patients in a Phase llb clinical study with BTI-320 in patients with type 2 diabetes. IPOXYN is an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes and is pre-clinical. The company produces and sells SUGARDOWN ® , a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com . 

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact: Boston Therapeutics, Inc. Anthony Squeglia Chief Financial Officer Phone: 603-935-9799 Email: anthony.squeglia@bostonti.com www.bostonti.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 317

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 414

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 217

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 121

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Van Horn Automotive Group Partners for Successful Dealership Sale

Updated Category News Views 928

Van Horn Automotive Group Sells Ford and Chevrolet Dealerships Performance Brokerage Services, recognized as a leader in dealership buy-sell transactions, has announced the acquisition of Van Horn Ford and Van Horn Chevrolet from Van Horn Automotive Group, marking an important transition for the dealerships. The new owners, Yelena and Alex Tovstanovsky of Sky Auto Mall,...

Continue Reading
G2 Goldfields Unveils Exciting Drilling Results at OKO

Updated Category News Views 136

G2 Goldfields Expands Mineral Resources at OKO G2 Goldfields Inc. (“G2”) (TSX: GTWO; OTCQX: GUYGF) has some exciting updates to share about its exploration activities at the vast 27,719-acre OKO-AREMU gold project. The company recently provided a significant update on their Mineral Resource Estimate (MRE), which now shows a remarkable total of 922,000 ounces of gold...

Continue Reading
Ecolectro Secures $10.5M Series A Funding for Green Hydrogen

Updated Category News Views 425

Ecolectro's Game-Changing Series A Funding Round Ecolectro has successfully completed a significant funding round, securing $10.5 million to enhance its innovative green hydrogen technology. The funding, led by Toyota Ventures, will enable Ecolectro to further develop its fully integrated and scalable electrolyzers, crucial for producing green hydrogen efficiently and...

Continue Reading
CEI Vision Partners Faces Data Breach Investigation: What to Know

Updated Category News Views 233

CEI Vision Partners Confronts Serious Data Breach Investigation In recent news, CEI Vision Partners, a prominent network of over 300 ophthalmologists and 700 optometrists, finds itself at the center of a significant data breach investigation. The investigation, led by the firm Schubert Jonckheer & Kolbe LLP, aims to uncover the details surrounding unauthorized access to...

Continue Reading
New Ethical AI Tools and Books Revolutionizing College Essays

Updated Category News Views 272

Innovative Solutions for College Essay Writing In light of recent prohibitions against artificial intelligence writing tools at major universities, students are navigating the challenges of crafting their college essays with greater scrutiny. College Essay Advisors has responded to this shift by introducing College EssAI, an innovative ethical AI platform designed to...

Continue Reading